Method of heavy metal intoxication prevention and treatment for animals

FIELD: veterinary.

SUBSTANCE: invention concerns animal breeding and veterinary. Method involves application of medicine. Chelavite microelement medication is used as preventive medicine in daily dosage of 0.2-0.4 ml per 10 kg of live weight perorally in the forage for constant application; daily dosage for treatment purposes comprises 0.6-0.8 ml per 10 kg of live weight for a month.

EFFECT: reduced lead and cadmium content in blood, milk and wool of animals, intoxication sign regress.

3 tbl, 2 ex

 

The invention relates to animal husbandry and veterinary medicine and can be used for the treatment and prevention of intoxication by heavy metals in animals. It is known that heavy metals - group of the periodic system of Mendeleev, which include lead, mercury, cadmium, cobalt, and some others, have a strong toxic effect on the body of the animal.

Cadmium referred to as toxic (immunotoxic) elements. Many of cadmium compounds are toxic. Chronic admise primarily affects the urinary and reproductive systems. The defeat of the bronchopulmonary system is accompanied by fibrotic changes and increase the risk of developing emphysema. Animals anemia associated with a decrease in the intestinal absorption of iron and red blood cell lysis. The main manifestations of excess cadmium in the body: cardiopathy, hypertension, pulmonary emphysema, osteoporosis, deformation of the skeleton, nephropathy, anemia, deficiency of zinc, selenium, copper, iron, calcium.

The lead refers to the substance of the first class of hazard, and its content in foods, drinking water, ambient air, etc. is highly regulated; the lead has a strong negative effect on the nervous system. Especially negative lead affects on the developing organism. Also proven the harmful effects of lead on heme the SEZ and the cardiovascular system. There is the potential for adverse effects of lead on the endocrine glands.

In medicine to reduce intoxication by heavy metals is used complexing pharmaceuticals, eliminating toxic metals and at the same time reducing the severity and symptoms of intoxication (Medmaravis, 2002, 237 S.; VIDAL, 2002, 307 S.). The most commonly used for these purposes are tetatsin (calcium-disodium salt Ethylenediamine-tetraoxane acid), pentoksil (4-methyl-5-oximetery, DTPA), succimer (dimercaprol) and other Data complexing drugs form with metals stable complexes, which are usually soluble in water and in the formation in the body relatively rapidly excreted in the urine.

However, these drugs can have adverse effects on the body, especially on the function and the parenchyma of the kidney. Prolonged use of drugs may cause excessive excretion of trace elements, allergic reactions, reduce the level of calcium in the blood, disorders of the gastrointestinal tract.

There is a method of treatment of chronic intoxication with salts of heavy metals in children, including the use of complexing drug - califona (EN 2089192, AK 31/663, OR 39/00, publ. 10.09.97, bull. No. 25). Xidian-monogalia the traveler, monosodium salt oksietilidendifosfonovaya acid, refers to the complexing compounds of phosphonic series, diphosphonates.

Also known is a method of treatment of dysmetabolic nephropathy children from ecologically unfavorable regions, including drug Limonta containing succinic acid (RU 2131730, AK 31/194, AR 13/12, publ. 20.06.99, bull. No. 17).

Also published a method for the treatment of chronic intoxication with heavy metals, including consistent use of drugs califona and succimer fractional rate within 2-7 days at therapeutic doses (EN 2285523, AK 31/194, publ. 20.10.2006, bull. No. 29).

A common disadvantage of known drugs is relatively high nephro - and hepatotoxicity. With long-term use of drugs accelerates the excretion of urine calcium and important trace elements such as iron, zinc, copper, which degrades the overall biochemical characteristics of blood, disturbed metabolism. In addition, it is unknown the use of these drugs for animals.

Also known trace element medicine for animals - Jelavic (EN 2227800 C1, publ. 20.06.2006, bull. No. 17, AC 1/175, AK 31/295), consisting of the following components, wt.%: 2Na - or 2K-salt Ethylenediamine - N, N1 - dinternal acid 15,0-35,0; Na - or K - salt of the amino acids 2,0-10,0; iron (III) 0,6-3,0; manganese (II) 0,5-2,5; copper (II) 0,05-0,25; zinc (II) 0.3 to 25; cobalt (II) 0,005-0,05; selenium (IV) 0,01-0,03; iodine (I) 0,03-0,08; water the rest. In this preparation the trace elements are in a balanced state in the form of chelates. The drug enhances the reproductive ability of animals, stimulates growth, development and productivity of agricultural and domestic animals.

However, no application of this drug for the treatment and prevention of intoxication by heavy metals in animals. In contrast to known drugs, which belong to the class of chelating agents that form complexes with metal ions found in the body, and therefore, in varying degrees, bringing them out of the body, Jelavic already contains a complex of a number of trace elements with polyaminoamide and therefore completely filled coordinating capacity complexone. Discovered the ability chelavite excrete heavy metals from the body of animals was an unexpected effect for this drug.

The objective of the invention is to develop a method for the treatment and prevention of intoxication by heavy metals in animals.

To solve this problem a method for the treatment and prevention of intoxication by heavy metals in animals with the use of a medicinal product according to the invention as drug use trace element preparation "Helau the t" for prevention in a daily dose of 0.2-0.4 ml per 10 kg body weight orally with food at a constant application; for treatment at a daily dose of 0.6-0.8 ml per 10 kg of body weight per month. The drug is added to feed and mix. If animals are in the area contaminated with heavy metals, use of prophylactic dosage of 0.2-0.4 ml per 10 kg body weight orally with food at constant use. In cases of acute poisoning Jelavic used at a dose of 0.6-0.8 ml per 10 kg of body weight per month.

An important advantage of this method is that the introduction of a whole range of vital trace elements in the composition can prevent their elimination from the body, strengthen the enzyme and hormonal processes and, thus, to normalize metabolism. This dramatically decreases the intoxication from exposure to heavy metals. The efficiency of the method can be illustrated by the following examples.

Example 1. The study of prevention of chronic intoxication with heavy metals in horses was conducted on a group of clinically healthy horses (n=15) aged 5-12 years contained in the conditions of private stables in the Leningrad region (North-Western region of the Russian Federation). The drug was given with feed at a dose of 0.6 ml per 10 kg body weight for 30 days. The research results are summarized in table 1-2.

Table 1/td>
The influence of the drug "Jelavic" on the content of heavy metals in horses
IndexBefore applying "Chelavite"After applying the "Chelavite"
in the blood
Cadmium, ug/mlaccounted for 10.39±a 3.872,0±1,01
Lead, ug/ml62,37±8,4541,12±6,67
in wool
Cadmium, µg/g0,035±0,010,010±0,0025
Lead, ug/g1,51±0,460,53±0,10

From the data of table 1 it follows that when using chelavite there was a decline in the content of Pb and Cd in blood 1.5 to 5.1, and wool 2.9-3.5 times.

Comparison of the effectiveness of chelavite conducted with the comprehensive drug "Gameplans", containing in its composition along with other components and trace elements (table 2).

Table 2
Comparative characteristics the influence of drugs "Jelavic and Gamebalance" on the content of heavy metals in horses
IndexData prior experienceAfter application of the "Gamebalance"After applying the "Chelavite"
in the blood
Cadmium, ug/mlaccounted for 10.39±a 3.878,45±1,952,0±0,01
Lead, ug/ml62,37±8,4555,67±10,5741,12±6,67
in wool
Cadmium, µg/g0,035±0,010,03±0,010,010±0,002
Lead, ug/g1,51±0,461,12±0,520,53±0,10

Drug gamebalance is similar to helvita composition and is also used for the treatment and prevention of anemia. But it contains electrolytes are not in the form of chelates, intramuscular introduction. This may explain the fact that the drug "Gameplans" does not contribute to the excretion of heavy metals.

Example 2. The study of prevention of chronic intoxication with heavy metals in Crospovidone on a group of clinically healthy cows (n=15) aged 2-6 years contained in the conditions of private farms in the Leningrad region (North-Western region of the Russian Federation). Jelavic asked with feed at a dose of 0.3 ml per 10 kg body weight for 30 days. From the presented data (table 3), it follows that when applying the drug Jelavic a decrease in the content of cadmium and lead in blood in 1,5-2,0 times, whey milk 2.2-3.2 times, and the lead content in hair of animals has decreased almost 50 times.

Table 3
The influence of the drug "Jelavic" on the content of heavy metals in cows
IndexBefore applying "Chelavite"After applying the "Chelavite"
in the blood
Cadmium, ug/mlof 4.49±1,112,12±0,95
Lead, ug/ml37,75±5,3224,4±2,17
in wool
Cadmium, µg/g0,12±0,030,09±0,01
Lead, ug/g1,91±0,12 0,04±0,001
serum milk
Cadmium, ug/ml3,12±0,030,97±0,03
Lead, ug/ml22,45±2,1210,12±3,11

Conclusion: the obtained data clearly indicate the high effectiveness of the drug "Jelavic" for the prevention and treatment of chronic intoxication with heavy metals in animals.

Method for the treatment and prevention of intoxication by heavy metals in animals, including the introduction of a drug, characterized in that the quality of drug use trace element preparation Jelavic" for prevention in a daily dose of 0.2-0.4 ml per 10 kg body weight orally with food at a constant application; for treatment at a daily dose of 0.6-0.8 ml per 10 kg of body weight per month.



 

Same patents:

FIELD: medicine, toxicology.

SUBSTANCE: treatment is carried out for 2 steps wherein in the first step the preparation xydofone is administrated in the dose 10-20 mg per kg of body mass per 24 h by continuous course for 21-30 days, and in the second step the chelate-forming pharmaceutical preparation with the stability constant 15-20 is administrated in the therapeutic doses by fractional schedule for 2-7 days. Invention promotes to the complete elimination of heavy metal salts from the body due to weakly or strongly fixed ions of heavy metals providing by the successive administration of xydofone and the chelate-forming pharmaceutical preparation, and provides membrane-stabilizing effect on renal tissues that, in turn, prevents arising possible iatrogenic complications. Invention can be used in treatment of chronic intoxication with heavy metals.

EFFECT: improved and enhanced effectiveness of treatment.

3 cl, 2 tbl

FIELD: coordination compounds synthesis.

SUBSTANCE: invention provides complex comprising calcium and [[(4R)-4[bis[carboxy.kappa.O)methyl]amino-.kappa.N]-6,9-bis[carboxy-.kappa.O)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecane-11-ylic acid-.kappa.N6,.kappa.N9,-kappa.011]-oxydato(6-)]-,6H, (MS-325) or its salt with physiologically acceptable cation in each case containing essentially no Gf-MS-325. Also described are pharmaceutical agent based on compounds according to claim 1 and a method for preparing galena composition, complex or its salt with physiologically acceptable cation according to claim 1 intended for preparation of pharmaceutical agent reducing effect produced by heavy metals as well as complex or its salt with physiologically acceptable cation according to claim 1 intended for preparation of pharmaceutical agent suitable for NMR diagnostics and/or diagnostic radiology, a method for amplifying patient's image in NMR tomography based on compounds according to claim 1 and above defined complex or its salt with physiologically acceptable cation in each case containing essentially no visualizing metal chelates and MS-325.

EFFECT: increased assortment of complexes with useful medicine-destination properties.

14 cl, 4 dwg, 30 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary science, in particular, to ways of reception of immunomodulatory and antiseptic compounds for prevention and treatment of infectious diseases of animals. The way of reception of a complex immunotropic antiseptic preparation for prevention and treatment of infectious diseases of animals includes mixing of an amber acid, novocaine, Dorogov's antiseptic-stimulator of the second fraction and formalin in water at a following parity of components, wt %: amber acid 1; DAS №2 4; novocaine 0.25; formalin 0.4; the distilled water - the rest, and sterilisation using autoclave treatment which is performed in a 1 atm regimen. Within 20 minutes. The received compound possesses antiseptic, immunomodulatory and trophicostimulating activity at a parenteral way of introduction.

EFFECT: rising of efficiency of the received preparation at treatment and prevention of infectious diseases of animals.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical and food industry, particularly a corrective composition for pathologic lipid, carbohydrate disbolism and antioxidant organism state disorder. The corrective composition for pathologic lipid, carbohydrate disbolism and antioxidant organism state involvement representing chitosan and ecinochrome A complex, vitamins and organic acids produced from addition to dehydrated and alcohol-processed chitosan of echinochrome A, ascorbic (vitamin C), lipoic (vitamin N), citric and succinic acids in spirit.

EFFECT: composition described above is effective for correction of pathologic lipid, carbohydrate disbolism and antioxidant organism state disorder.

3 cl, 6 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to infectious diseases and can be used for prevention of herpes simplex disease recurrence. For this purpose patients in intra-recurrence period are administered complex of measures aimed at reduction of skin and mucosa acidity: special diet, favouring shift of pH of tissues and biological fluids toward alkali side, consumption of 3-4 litres of drinking water a day, limiting consumption of products possessing "acidifying" properties, salt and pickles, exclusion of food vinegar and containing it products from diet. During period of high risk of disease recurrence development additionally perorally administered is 0.25% solution of sodium citrate 100 ml per hour during 10 hours daily. After each two weeks of carrying our anti-recurrence measures 5-7 day recess is administered.

EFFECT: invention allows to increase efficiency of anti-recurrence prophylaxis due to suppression of retraction of herpes simplex viruses and their leaving ganglia nerve cells by reducing skin and mucosa acidity.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: recurrent lower limb erysipelas is ensured by introducing intracellular antibiotic and autoblood hemolysate. It is combined with non-acute group therapy to raise skin acidity, including: acidulation diet, thereby limiting alkalisation products, with salt, canned food, salty and smoked products eliminated. It is added to daily oral introduction of 5% acetic acid solution 5.0 ml diluted in boiled water 100.0 ml. Affected limb skin is treated regularly with acidulation liquid containing 20% acetic acid solution 160.0 ml and glycerine 40.0 ml. Every two weeks of anti-relapse actions are alternated with 1 week break.

EFFECT: higher efficiency of anti-relapse prevention ensured by raised skin acidity, activation of neutrophilic phagocytes normalising microbiocoenosis of affected limbs.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, pharmaceutics and organic chemistry and concerns application of kinurenin 3-hydroxylase inhibitors, selected from compounds given below for obtaining medication for treating diabetes, novel compounds selected from -2-benzilthio-4-phenyl-4-oxobutanoic acid; 2-(4'-methylphenylthio)-4-phenyl-4-oxobutanoic acid; 2-(4'-chlorphenylthio)-4-phenyl-4-oxobutanoic acid; 2-(4'-fluorphenylthio)-4-phenyl-4-oxobutanoic acid; 2-(4'-methoxyphenylthio)-4-phenyl-4-oxobutanoic acid; 2-phenylthio-4-phenyl-4-oxobutanoic acid; 2-carboxymethylthio-4-phenyl-4-oxobutanoic acid; 2-cyclohexylthio-4-phenyl-4-oxobutanoic acid; 2-(2'-naphtylthio)-4-phenyl-4-oxobutanoic acid; ethyl 2-phenylthio-4-phenyl-4-oxobutanoate; ethyl 2-(4'-fluorophenylthio)-4-phenyl-4-oxobutanoate; ethyl 2-(4'-chlorphenylthio)-4-phenyl-4-oxobutanoate; ethyl 2-(4'-methylphenylthio)-4-phenyl-4-oxobutanoate; ethyl 2-(4'-methoxyphenulthio)-4-phenyl-4-oxobutanoate; ethyl 2-(4'-naphtylthio)-4-phenyl-4-oxobutanoate; ethyl 2-cyclohexyltio-4-phenyl-4-oxobutanoate; ethyl 2-benzylthio-4-phenyl-4-oxobutanoate; 2-phenylthio-4-(4'-methoxyphenyl)-4-oxobutanoic acid; 2-(4'-fluorophenylthio)-4-(4'-methoxyphenyl)-4-oxobutanoic acid; 2-(4'-chlorphenylthio)-4-(4'-methoxyphenyl)-4-oxobutanoic acid; 2-(4'- methylphenylthio)-4-(4'-methoxyphenyl)-4-oxobutanoic acid; 2-(4'- methoxyphenylthio)-4-(4'-methoxyphenyl)-4-oxobutanoic acid; 2-(2'-naphtylthio)-4-(4'-methoxyphenyl)-4-oxobutanoic acid; 2-cyclohexylthio-4-(4'-methoxyphenyl)-4-oxobutanoic acid; 2-benzylthio-4-(4'-methoxyphenyl)-4-oxobutanoic acid; 2-phenylthio-4-(4'-chlorphenyl)-4-oxobutanoic acid; 2-(4'-fluorophenyltio)-4-(4'-chlorphenyl)-4-oxobutanoic acid; 2-(4'-chlorphenyl)-4-(4'-chlorphenyl)-4-oxobutanoic acid; 2-(4'-methylphenylthio)-4-(4'-chlorphenyl)-4-oxobutanoic acid; 2-(4'-methoxyphenylhtio)-4-(4'-chlorphenyl)-4-oxobutanoic acid; 2-(2'-naphtylthio)-4-(4'-chlorphenyl)-4-oxobutanoic acid; as well as their possible geometric and/or optic isomers, and their possible tautomeric forms, solvates and hydrates of said compounds, as well as their possible salts with pharmaceutically acceptable acid or base or pharmaceutically acceptable pro-drugs of said compounds, as well as pharmaceutical compositions, including them, for treatment or prevention of diabetes or its complications.

EFFECT: obtaining medications for treating diabetes.

4 cl, 11 dwg, 4 tbl, 3 ex

FIELD: veterinary.

SUBSTANCE: invention relates to veterinary. Preparation is prepared by dissolving in distilled water components with the following ratio, %: "АСД-Ф" №2 4.0; succinic acid 1.0; iron sulphate 0.2; copper sulphate 0.01; zinc sulphate 0.01; cobalt sulphate 0.1; novocaine 0.25; polyethylene glycol 3.0; distilled water - the remaining part, pH of solution is drought to 7.0 and sterilised by autoclaving in 1.2 atm mode during 20 minutes.

EFFECT: invention ensures obtaining immunotropic preparation of injection form with wide spectrum of biological activity for prevention and treatment of microelementoses, metabolic disbalance, increase of animal organism resistance.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to anaesthesiology, and can be used at the patients operated in the conditions of epidural anaesthesia. For this purpose Gelatinolum preparation is administered to the patient with rate of 80-90 drops a minute by means of infusional system before an epidural space catheterisation. Simultaneously by means of additional infusional system Reamberine preparation is administered with rate of 80-90 drops in a minute. Reamberine and Gelatinolum parity makes 1:1. During operation intake of Reamberine and Gelatinolum in the same parity is performed with rate of 50-60 drops in a minute.

EFFECT: method allows improving and stabilising a hemodynamic and bioelectric activity of heart at patients during operation due to combined application of these preparations allowing strengthening energy processes in a cell against maintenance of a hemodynamic.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: using for pathogenetic therapy of tick-borne neuroinfections. Citoflavin is injected to patients with tick-borne neuroinfections during an early reconvalescence period.

EFFECT: increase of treatment efficiency due to drop of endogenous nitrogen oxide production.

3 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to orthopedic surgery and can be used at orthopedic operative measures with a prognosticated significant or massive hemorrhage, in particular, during endoprosthesis replacement of joints. For this purpose directly ahead of anaesthesia provide achievement of acute euvolemic hemodilutions by taking of an autoblood with a restoration of hemorrhage with crystalloids. Provide a controlled hypotension by administering of anaesthetic during all operative measure. For provision of intraoperative normovolemias perform administering of Gelofuzine and Reamberine preparations. Before wound mending, perform a reinfusion of the autoblood taken before the operation. Then carry out drainage of an operational wound performing in step by step with a reinfusion of drainage blood of high degree of clearing. Administer anticoagulants in 12 hours after an operative measure.

EFFECT: prevention of implantation syndrome.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to experimental pharmacology. Method includes introduction of actoprotective preparation reamberinum intravenously in doze of 10 mg/kg of animal weight in morning hours 40 minutes before carrying out Porsolt tests and tests of vertical screen-net.

EFFECT: extending arsenal of means for enhancing work capacity of laboratory animals in experiment.

2 tbl, 2 ex

FIELD: polymer materials in medicine.

SUBSTANCE: aqueous solution according to invention contains 0.05-0.11 mole/L oxalic acid and 0.02-0.17 mole/L alkali metal salt(s). Treatment of polymethylmethacrylate materials with such solution allows complete removal of residual monomer without alteration of molecular mass and supramolecular structure of polymer material.

EFFECT: reduced risk of rejection of implants and improved mechanical and optical properties thereof.

1 tbl, 3 ex

FIELD: pharmaceutics, veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating hypomicroelementosis in different farm and domestic animals, furred animals, and, also, for enhancing the growth in animals, and treating a number of specific diseases and, also, for maintaining microelemental composition of feedstuffs. The suggested preparation includes chelated complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with organic ligand of complexone type and water. According to the innovation as a chelation ligand it contains trisodium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid at a certain ratio of components. The innovation provides to obtain preparation in soluble form being capable to be well digested by the animal.

EFFECT: higher efficiency.

FIELD: medicine, neurology, traumatology, neurosurgery.

SUBSTANCE: the present innovation deals with treating acute craniocerebral traumas (CCT). Since the first hours of therapy it is necessary to perform intravenous drop injection of 2-ethyl-6-methyl-3-hydroxypyridine succinate per 200 mg twice daily in case of severe degree of disease and per 200 mg once daily in case of average and light degrees of the trauma. The method provides detoxication effect in acute period of CCT due to recently established antitoxic action of the preparation suggested , that is accelerated degradation and withdrawal of toxic metabolites out of cerebrospinal liquid.

EFFECT: higher efficiency of therapy.

3 ex, 3 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes an agent for removing the post-narcosis depression after combined anesthetic assistances with applying sedative and narcotic preparations. As such agent the preparation "Reamberin" is used based on succinic acid that is a natural metabolite in human body. The preparation provides reducing time for adequate spontaneous breathing and awaking time by 1.5-fold and the absence of complications and negative adverse responses.

EFFECT: valuable properties of agent.

4 dwg, 3 ex

FIELD: medicine, narcology.

SUBSTANCE: invention relates to hepatoprotective and anti-encephalopathic agent used for reducing alcoholic intoxication. Invention comprises components based on succinic, fumaric, glutamic acids and, additionally, at least one vitamin of B group. Agent can comprise additionally vegetable extracts or their mixture, L-carnitine, glycine, L-arginine, taurine and/or their mixture, methylsulfonylmethane, dihydroquercitin, dimethylsulfoxide or their mixture, nicotinamide or nicotinic acid or their mixture, energy source and sweetening agent. Also, invention proposes a method for reducing alcoholic intoxication, prophylaxis and removing withdrawal syndrome, liver protection, among them, in non-alcoholic intoxication and protection against encephalopathy. Invention provides described effects without qualifying medical control.

EFFECT: valuable medicinal properties of agent.

16 cl, 3 tbl

FIELD: medicine, surgery.

SUBSTANCE: one should introduce solution "Rheamberin 1.5%"intravenously with infusomates at the dosage of 5 ml/kg/d during the next 5 d. Then, 1-2 h later, one should infuse intravenously "Dalargin" at 30 mg/kg/d dissolved in 60 ml 0.9% sodium chloride at the rate of 120 ml/h for 5 d. Additionally, 4-5 h after "Dalargin" injection it is necessary to perform daily intravenous He-Ne laser irradiation of blood beginning since the first day at wave length being 0.63 mcm, power 1 mW, exposure 50-60 min, course lasts for 5 d. The method enables to interrupt intestinal paresis in case of vertebral traumas and wounds in earlier terms.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, physiotherapy, health resort treatment.

SUBSTANCE: one should affect with balneo-, peloido-, EHV-therapy daily at the following sequence: 9 - 11 a.m. - balneotherapy, 8-10 procedures/course, 11 a.m. - 1 p.m - therapy, 10 procedures/course, 2 p.m. - 4 p.m.- peloidotherapy, 8-10 procedures/course. Moreover, about 2-3 d before this impact one should prescribe a food additive as succinic acid at the dosage of 0.5 g thrice daily after meals for 14 -16 d. The method enables to shorten the frequency of appearance and degree of balneoreactions, shorten therapy terms without any decrease of productivity.

EFFECT: higher efficiency of therapy.

4 cl, 3 ex, 5 tbl

FIELD: physiotherapy and health resort treatment.

SUBSTANCE: method envisages drinking mineral water, performing intragastric electrophoresis with mineral water, magnet-laser therapy, massage, and baths. Additionally, 2-3 days before physiotherapy and during physiotherapy, biologically active additive "succinic acid" is administered in daily dose 3 x 0.5 g after meal. Intragastric and magnet-laser therapy are performed every day consecutively without interval between them. Treatment course consists of 8-10 procedures. Method allows achieving stable remission in case of indicated diseases thanks to integrated positive effect produced on inflammatory process, velocity of epithelization of ulcerous and erosive defects, acid-forming, neutralizing, and motor functions in gastroduodenal region on the whole.

EFFECT: enhanced treatment efficiency.

5 tbl, 2 ex

Up!